| Name | Title | Contact Details |
|---|
Image Owl creates complete, convenient , accurate and insightful cloud-based solutions to analyze and manage your diagnostic medical imaging and radiotherapy quality assurance needs.
At Tomah Health, we are inspiring health, wellness and balance for patients, families and our community, together in care. We have been caring for our community since 1952 and Tomah Health advances excellence in care by providing quality, compassionate healthcare close to home. We are growing for you and our community to continue to provide superior healthcare for generations to come.
Established in 1968, Providence Community Health Centers, Inc. is the largest primary health care provider in Providence, Rhode Island. In addition to eight health centers, we also operate a school-based program, and a dental clinic serving children under the age of 19 and pregnant women. PCHC is a non-profit health care organization and the only Federally Qualified Heath Center (FQHC) in Providence. We have recruited some of the area`s most prestigious physicians and empowered them to make a difference providing quality care to more than 50,000+ residents of Providence and its surrounding areas. As we continue to grow our network of neighborhood-based clinics, PCHC is seeking physicians to join our team. Our services include: Family Practice, Internal Medicine, Pediatrics, Obstetrics, Gynecology, Behavioral Health, Dental Care and Express Care (urgent care) alongside with selected specialty services.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
DarioHealth Corp. is a leading global digital health company serving its users with dynamic mobile health solutions.